Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Giulio Cavalli and Lorenzo Dagna.
Giulio Cavalli
Connection Strength
15.536
Lorenzo Dagna
  1. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply. Lancet Rheumatol. 2021 Apr; 3(4):e248-e249.
    View in: PubMed
    Score: 0.933
  2. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
    View in: PubMed
    Score: 0.927
  3. Anakinra in COVID-19-How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al. Arthritis Rheumatol. 2021 03; 73(3):549.
    View in: PubMed
    Score: 0.927
  4. The right place for IL-1 inhibition in COVID-19. Lancet Respir Med. 2021 03; 9(3):223-224.
    View in: PubMed
    Score: 0.925
  5. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatology (Oxford). 2021 01 05; 60(1):465-467.
    View in: PubMed
    Score: 0.922
  6. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020; 11:598308.
    View in: PubMed
    Score: 0.919
  7. Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. Eur J Intern Med. 2020 12; 82:23-24.
    View in: PubMed
    Score: 0.910
  8. Effect of anakinra in COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Sep; 2(9):e524-e525.
    View in: PubMed
    Score: 0.894
  9. Anakinra for patients with COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Jul; 2(7):e383-e384.
    View in: PubMed
    Score: 0.889
  10. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
    View in: PubMed
    Score: 0.881
  11. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 25; 21(1):69.
    View in: PubMed
    Score: 0.811
  12. Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. Int J Cardiol. 2018 Feb 01; 252:21-23.
    View in: PubMed
    Score: 0.753
  13. Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. Front Immunol. 2017; 8:131.
    View in: PubMed
    Score: 0.704
  14. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. J Clin Rheumatol. 2021 Jun 01; 27(4):e143-e146.
    View in: PubMed
    Score: 0.237
  15. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
    View in: PubMed
    Score: 0.236
  16. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvasc Res. 2021 01; 133:104071.
    View in: PubMed
    Score: 0.226
  17. Mavrilimumab for severe COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Nov; 2(11):e662-e663.
    View in: PubMed
    Score: 0.225
  18. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
    View in: PubMed
    Score: 0.224
  19. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
    View in: PubMed
    Score: 0.222
  20. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020 01 01; 59(1):171-175.
    View in: PubMed
    Score: 0.215
  21. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018 12 04; 169(11):819-820.
    View in: PubMed
    Score: 0.195
  22. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018 11; 57:e11-e12.
    View in: PubMed
    Score: 0.195
  23. Myocarditis: An Interleukin-1-Mediated Disease? Front Immunol. 2018; 9:1335.
    View in: PubMed
    Score: 0.193
  24. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. Front Immunol. 2018; 9:1233.
    View in: PubMed
    Score: 0.193
  25. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. Oncoimmunology. 2018; 7(7):e1440929.
    View in: PubMed
    Score: 0.190
  26. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2017 12 01; 56(12):2256.
    View in: PubMed
    Score: 0.186
  27. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017; 6(6):e1318237.
    View in: PubMed
    Score: 0.178
  28. Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al. Clin Exp Rheumatol. 2017 Mar-Apr; 35 Suppl 103(1):221.
    View in: PubMed
    Score: 0.177
  29. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci U S A. 2017 02 28; 114(9):2313-2318.
    View in: PubMed
    Score: 0.176
  30. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021 10; 27(10):1752-1760.
    View in: PubMed
    Score: 0.060
  31. A virus-free cellular model recapitulates several features of severe COVID-19. Sci Rep. 2021 09 01; 11(1):17473.
    View in: PubMed
    Score: 0.060
  32. Testosterone in males with COVID-19: A 7-month cohort study. Andrology. 2022 01; 10(1):34-41.
    View in: PubMed
    Score: 0.060
  33. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021 Oct; 3(10):e690-e697.
    View in: PubMed
    Score: 0.060
  34. Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. Minerva Anestesiol. 2021 08; 87(8):891-902.
    View in: PubMed
    Score: 0.059
  35. The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. J Clin Med. 2021 May 04; 10(9).
    View in: PubMed
    Score: 0.059
  36. Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J Neuroimmune Pharmacol. 2021 Mar; 16(1):211.
    View in: PubMed
    Score: 0.058
  37. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med. 2021 04; 86:34-40.
    View in: PubMed
    Score: 0.058
  38. Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J Neuroimmune Pharmacol. 2021 03; 16(1):1-3.
    View in: PubMed
    Score: 0.057
  39. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
    View in: PubMed
    Score: 0.056
  40. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
    View in: PubMed
    Score: 0.055
  41. Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Front Pharmacol. 2019; 10:296.
    View in: PubMed
    Score: 0.051
  42. Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. J Neurol. 2018 Feb; 265(2):273-284.
    View in: PubMed
    Score: 0.047
  43. QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. Int J Cardiol. 2017 07 15; 239:33.
    View in: PubMed
    Score: 0.045
  44. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017; 8:369.
    View in: PubMed
    Score: 0.045
  45. Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. Oncoimmunology. 2016 Jul; 5(7):e1181244.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.